摘要
目的观察曲美他嗪治疗慢性缺血性心肌病心力衰竭的临床疗效。方法120例慢性缺血性心肌病心力衰竭患者分为2组,对照组(n=58)给予常规抗心力衰竭治疗,观察组(n=62)在常规抗心力衰竭治疗基础上加服曲美他嗪20 mg,每日3次,疗程均为3个月,应用多普勒超声心动图观察2组治疗前、治疗后1个月和6个月的心脏结构及功能改变情况。结果观察组总有效率(91.9%)明显高于对照组(77.6%),差别有统计学意义(P<0.05)。2组治疗前左室射血分数(LVEF)、左室舒张末内径(LVEDD)、左室收缩末内径(LVESD)和E峰A峰流速比值(E/A)比较差别均无统计学意义(P>0.05);疗程结束后1个月及6个月复查时,2组LVEF、LVEDD、LVESD均比治疗前有明显改善,且观察组比对照组改善更明显(P<0.05),但E/A值比较差别无统计学意义(P>0.05)。结论曲美他嗪能够改善缺血性心肌病心力衰竭患者心脏结构,明显改善心脏功能。
Objective To observe the therapeutic effect of trimetazidine on patients with chronic ischemic cardiomyopathy heart failure. Methods One hundred and twenty patients with chronic ischemic cardiomyopathy heart failure were divided into two groups. The patients were treated with routine anti-failure therapy in control group（ n =58） ,based on this,the patients were treated with trimetazidine in observation group（ n =62） ,20 rag,three times per day for three months. The cardiac structure and function were measured with Doppler echocardiography in two groups before and after one month and six months treatment. Results The total effective rate was higher obviously in control group than that in observation group （ P 〈 0.05 ）. Before treatment, there was no statistical difference in the left ventricular ejection fraction （LVEF）, left ventricular end-diastolic dimension （LVEDD）, left ventricular end-systolic dimension（LVESD） and E/A between two groups （P 〉 0.05 ）. One month and six months later after treatment, the LVEF, LVEDD and LVESD were improved obviously, and the improvement was more in observation group（ P 〈 0. 05 ）. There was no obvious change in E/A in two groups （P 〉 0.05 ）. Conclusion Trimetazidine can improve cardiac structure and function in patients with chronic ischemic cardiomyopathy heart failure.
出处
《新乡医学院学报》
CAS
2010年第2期176-178,共3页
Journal of Xinxiang Medical University
关键词
缺血性心肌病
慢性心力衰竭
曲美他嗪
ischemic cardiomyopathy
chronic heart failure
trimetazidine
